Theriva publishes Phase 1 trial results for VCN-01 showing 17-month survival in head & neck cancer

Filed June 11, 2026 · Period ending June 11, 2026 · ~1 min read

Key Changes

• high

  Phase 1 trial of VCN-01 combined with durvalumab achieved median overall survival of 17.3 months in the high-dose sequential arm for heavily pre-treated head and neck cancer patients who had failed prior checkpoint inhibitors.

  Item 7.01: Press Release verify on EDGAR →
• high

  Trial results published in Clinical Cancer Research journal, providing peer-reviewed validation of VCN-01's clinical data in 20 patients with refractory or metastatic head and neck squamous cell carcinoma.

  Item 7.01: Press Release verify on EDGAR →
• medium

  Biomarker data confirmed VCN-01 successfully replicated inside tumors, with PH20 enzyme levels elevated in all tested patients and detectable for up to 28 days, supporting the therapy's mechanism of action.

  Item 7.01: Press Release verify on EDGAR →